Osimertinib Treats CNS Metastases in NSCLC

Cancer Discovery - United States
doi 10.1158/2159-8290.cd-nb2018-121
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors

Unknown

Publisher

American Association for Cancer Research (AACR)

Related search

MA26.10 CNS Activity of Ramucirumab in Combination With Osimertinib in Patients With Advanced T790m-Positive EGFR-Mutant NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

182P: Intracranial Response to Nivolumab in NSCLC Patients With Untreated or Progressing CNS Metastases

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2016English

Elemene Treatment for NSCLC With Multiple CNS Metastases: A Case Report and Literature Review

OncoTargets and Therapy
OncologyPharmacology
2018English

Osimertinib Plus Durvalumab Versus Osimertinib Monotherapy in EGFR T790m-Positive NSCLC Following Previous EGFR-TKI Therapy: CAURAL Brief Report

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

P048 Clinical Efficacy of Osimertinib Mesylate Tablets in Treatment of Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P2.01-02 Osimertinib for EGFR-Positive Advanced NSCLC With Brain Metastases: Preliminary Analysis of an Open-Label, Two-Arm, Phase 2 Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Osimertinib as First-Line Therapy in Advanced NSCLC: A Profile of Its Use

Drugs and Therapy Perspectives
Pharmacology
2018English

CNS Metastases Needn't Rule Out Trial Inclusion

Cancer Discovery
Oncology
2018English

JCSE01.21 Different Responses to Osimertinib in Primary and Acquired EGFR T790m-Mutant NSCLC Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy